TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05894239: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy Af

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 230 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT05894239 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05894239 Rescue Dossier →